Edurant (rilpivirine), in combination with other antiretroviral drugs, was approved by the Food and Drug Administration to treat the HIV-1 infection in adults who have not taken any prior treatment HIV
HIV is the virus that causes AIDS. Edurant, an inhibitor of the so-called non-nucleoside reverse transcriptase inhibitor (NNRTI), blocks the ability of the virus to reproduce. The pill is taken once a day with food, the FDA said in a press release.
Edurant was evaluated in a pair of 48 weeks of studies on 1 368 adults infected with HIV. Over the other NNRTIS, efavirenz, Edurant was also effective for reducing the quantities of virus in the blood of a person, the Agency said.
The most commonly reported side effects were depression, insomnia, headache and rash.
Given that Edurant not reverse HIV infection, people must continue to take the drug, in combination with other anti-HIV drugs, to prevent HIV-related disease, the FDA said.
Edurant is produced by Tibotec Therapeutics, based in Raritan, N.J.
No comments:
Post a Comment